Our analyses demonstrated favorable mortality impacts across multiple variables: Both diabetic and non-diabetic GLP-1 users had lower relative all-cause mortality over the study period, with very similar reductions observed in both groups compared to non-GLP-1 users
for BG-SS-Lumi4-Tb, or where the labour-intensive nature of the experiments precluded multiple repeats, such as electron microscopy
For clients managing type 2 diabetes, we offer supportive guidance during medication transitions, such as moving from semaglutide GLP-1 to tirzepatide
GLP-1, or glucagon-like peptide-1, is a hormone that regulates blood sugar levels
The stimulated metabolic rate from uncontrolled hyperthyroidism, combined with appetite suppression from semaglutide, creates unpredictable metabolic stress
Proactive declaration with documentation is faster than being stopped for undeclared items